Glenmark Pharmaceuticals
Edit

Glenmark Pharmaceuticals

http://www.glenmarkpharma.com/
Last activity: 30.12.2024
Active
Categories: BusinessCultureDevelopmentGrowthMarketMedTechProductSpecialtySupplyTalent
Glenmark is a leading global innovative pharmaceutical company committed to enriching lives worldwide.

Our vision is to discover possibilities and make lives of patients better across the globe by developing cures for unmet medical needs. We have a rich pipeline of innovative molecules in various phases of development which are targeted in areas of oncology, respiratory and dermatology.

Our Generics business spans across multiple geographies with the US being our largest market followed by India. Our effort is to make high quality affordable medication accessible to patients across the world. Through our generics medicines we impact over 100 million patients each year globally. We are also a global supplier of high quality API products and a preferred partner for pharmaceutical companies worldwide.

Our 14,000 employees globally are dedicated towards our goal of enriching lives globally. Our values - Achievement, Respect and Knowledge bind our workforce together and consistently fuel our growth. At Glenmark, we have created a culture which allows our talent to deliver their best and create positive outcomes for themselves, the organization and the community at large.

Through Glenmark Foundation, our CSR activities are largely focused in the areas of Child Health and over the years we have impacted over 900,000 lives globally.

For more information, log onto www.glenmarkpharma.com.
Followers
416.72K
Website visits
135K /mo.
Mentions
61
Location: India, Maharashtra, Mumbai
Employees: 10001+
Founded date: 1977

Mentions in press and media 61

DateTitleDescription
31.12.2024Alphamab Oncology's Bold Steps in Cancer Treatment: A New Era of Bispecific Antibody-Drug ConjugatesIn the relentless battle against cancer, innovation is the sword that cuts through despair. Alphamab Oncology, a biopharmaceutical company based in Suzhou, China, is wielding this sword with precision. Recently, the company announced signif...
30.12.2024Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian CancerSUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National M...
26.12.2024IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was ApprovedSUZHOU, China, Dec. 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bis...
15.12.2024Aurobindo, Glenmark, Zydus recall products in US over manufacturing issuesDrug makers Aurobindo Pharma, Glenmark and Zydus are recalling products in the US market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), Aur...
13.12.2024Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line...
11.12.2024Oriola renews operating model and management team to accelerate strategy executionOriola renews operating model and management team to accelerate strategy execution Wed, Dec 11, 2024 08:15 CET Report this content Oriola Corporation Stock Exchange Release 11 December 2024 at 9:15 a.m. EET Oriola renews operating model and...
11.11.2024Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispec...
28.10.2024Japan's Political Storm: Markets Brace for ImpactJapan stands at a crossroads. The recent general election has sent shockwaves through the political landscape, leaving uncertainty in its wake. The ruling coalition, led by Prime Minister Shigeru Ishiba, is poised to lose its parliamentary ...
25.10.2024Morning Bid: Markets becalmed, eyes on JapanAsian MarketsMorning Bid: Markets becalmed, eyes on Japan By Jamie McGeeverOctober 24, 20249:48 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link CommentaryBy Jamie McGeever Media members observe ...
01.09.2024Trade Spotlight: How should you trade UPL, Glenmark Pharma, GSPL, Radico Khaitan, RVNL, and others on Monday?Stocks Picks for Short Term Trade Watchlist Portfolio Message Set Alert livebselivenselive Volume Todays L/H More × The benchmark indices continued their record-high streak despite volatility on August 30, with 1,366 shares advancing and 98...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In